IGC Pharma Inc. has released its financial results for the fiscal year ended March 31, 2025. The company's revenue decreased to $1.2 million in Fiscal 2025 from $1.3 million in the previous year, primarily due to the conclusion of infrastructure projects, which generated $164 thousand in revenue in Fiscal 2024 but contributed nothing to the revenue in Fiscal 2025. However, revenue from the Life Sciences segment increased to $1.271 million from $1.181 million, highlighting the company's strategic focus on this area. The company reported a net loss of approximately $7.1 million for Fiscal 2025, an improvement from the $13 million net loss reported in Fiscal 2024. This marks a reduction of about $6 million in net loss year-over-year. In terms of strategic developments, IGC Pharma has made significant clinical progress in Alzheimer's innovation and expanded its strategic initiatives. The company also raised about $4.64 million through private equity placements and an at-the-market offering program during the fiscal year. Additionally, subsequent to the fiscal year-end, the company extended its loan agreement with O-Bank, Co., Ltd. for one year with minor modifications.